T cell receptors
US-2019330301-A1 · Oct 31, 2019 · US
Human alpha fetoprotein-specific t cell receptors and uses thereof
US12173045B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-12173045-B2 |
| Application number | US-202117353409-A |
| Country | US |
| Kind code | B2 |
| Filing date | Jun 21, 2021 |
| Priority date | May 12, 2017 |
| Publication date | Dec 24, 2024 |
| Grant date | Dec 24, 2024 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
T cell receptors that specifically recognize hAFP 158 and methods of their use are provided.
First claim
Opening claim text (preview).
We claim: 1. A method for treating an HLA-A2/Hafp 158 expressing cancer in a subject in need thereof, the method comprising administering said subject a therapeutically effective amount of CD4 and/or CD8 T cells comprising a recombinant T cell receptor (TCR) comprising a Vα domain and a Vβ domain, (a) the Vα domain comprising three complementarity determining regions (CDRs), CDR1, CDR2 and CDR3, wherein CDR1 comprises an amino acid sequence of DRNVDY (residues 47 to 52 of SEQ ID NO:2), wherein CDR2 comprises an amino acid sequence of IFSNGE (residues 70 to 75 of SEQ ID NO:2), and wherein CDR3 comprises an amino acid sequence set forth in SEQ ID NO: 29; and (b) the Vβ domain comprising three CDRs, CDR1, CDR2 and CDR3, wherein CDR1 comprises an amino acid sequence of NSHNY (residues 44 to 48 of SEQ ID NO:11), wherein CDR2 comprises an amino acid sequence of SYGAGN (residues 66 to 71 of SEQ ID NO: 11), and wherein CDR3 comprises an amino acid sequence set forth in SEQ ID NO: 37. 2. The method of claim 1 , wherein the cancer is hepatocellular carcinoma. 3. The method of claim 1 , wherein the T cell is autologous to the subject. 4. The method of claim 1 , wherein the TCR is a humanized TCR. 5. The method of claim 1 , wherein the T cell is a human cell.
Assignees
Inventors
Classifications
Alpha-feto protein · CPC title
T-cell receptors [TCR] · CPC title
T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells · CPC title
Liver · CPC title
characterised by the dose, timing or administration schedule · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US12173045B2 cover?
- T cell receptors that specifically recognize hAFP 158 and methods of their use are provided.
- Who is the assignee on this patent?
- Univ Res Inst Inc Augusta
- What technology area does this patent fall under?
- Primary CPC classification C07K14/7051. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Dec 24 2024 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 4 related publications on this page (citations in our corpus or others sharing the same primary CPC).